PROK

1.0411.79%
WF

William F. Doyle

Executive Chairman

Mr. William F. Doyle, also known as Bill, is a Co-Founder & Director of Sequel Med Tech, LLC. Mr. Doyle has been an Independent Director of ProKidney Corp. since January 2022 and serves as its Lead Independent Director since May 2025. He served as Non-Management Director of OptiNose, Inc. since 2010 until December 11, 2020. Mr. Doyle served as Director of OptiNose US Inc. since 2010. Mr. Doyle has been Executive Chairman of Novocure Limited since 2016 and as Chairman of the Board since 2009 and also has been its Director since 2004. Mr. Doyle serves as an Advisor of Cutlass Capital, LLC. He was Managing Partner at WFD Ventures LLC since 2003 and also served as its Managing Director since 2002, which he co-founded (2002 – 2022). He was Independent Director of Elanco Animal Health Incorporated from December 14, 2020 until March 17, 2025. He has been an Executive Chairman of NovoCure Inc. since May 11, 2016. He served as an Executive Chairman of Blink Health Ltd. from November 2016 to January 2021. He had been Director and Lead Independent Director of Minerva Neurosciences, Inc. from December 10, 2017 to May 03, 2023 and February 2018 respectively. He serves as Executive Director of Inventure, LLC. He was a Member of the Investment team at Pershing Square Capital Management, L.P. from October 2014 to 2016. He served as the Managing Director of Insight Venture Partners LLC, Insight Venture Partners VI, L.P. Insight Venture Partners V, L.P. Insight Venture Partners IV, L.P. He served as Vice President of Johnson & Johnson Innovation - JJDC, Inc. (Johnson & Johnson Development Corporation). He served as a Member of Johnson & Johnson's Medical Devices and Diagnostics Group Operating Committee and was Vice President of Licensing and Acquisitions. He served as Management Consultant at McKinsey & Company, Inc. He was the Founder of Durel Corporation. He was Chairman of the Worldwide President of Biosense-Webster, Inc. and a member of the Boards of Cordis Corporation and Johnson & Johnson Development Corporation, Johnson & Johnson’s venture capital subsidiary. While at Johnson & Johnson, Mr. Doyle was also Chairman of the Medical Devices Research and Development Council and President of Biosense-Webster, Inc. He serves as a Director of Realink Corporation, CareMessage Inc. Aspire Bariatrics, Inc. Doctors Research Group, Inc. and Prisma Medical Technologies LLC. He served as a member of the OptiNose AS Board of Directors from 2004 to 2010. He served as an Independent Director of Zoetis Inc. from February 03, 2015 to May 17, 2016. He served as a Director of Revitas Inc. from December 1999 to August 24, 2005, Andrew Technologies, LLC until September 15, 2015 and Vision-Sciences Inc. from 2002 to August 12, 2005. He served as a Director of Cadence Network, Inc. Avisena, Inc. BionX Medical Technologies, Inc. NanoPass Technologies Ltd. BioScale, Inc. (alternative name ProterixBio, Inc.), GlobalCare Inc. OnStation Corporation, RxCentric.com, Inc. IKANO Communications, Inc. and Cleanwise, Inc. Mr. Doyle serves on Harvard Business School Board of Dean Advisors. He served as a Non-Executive Director at Advanced Surgical Concepts Limited until April 08, 2016. Mr. Doyle holds an S.B. in Materials Science and Engineering from the Massachusetts Institute of Technology and M.B.A. from Harvard Business School.

Positions